硼替佐米
- 价格: ¥99/瓶
- 发布日期: 2019-04-01
- 更新日期: 2025-10-15
产品详请
| 产地 |
加拿大
|
| 品牌 |
进口
|
| 货号 |
02-675700
|
| 包装规格 |
1mg,10mg
|
| 纯度 |
98%
|
| CAS编号 |
179324-69-7
|
| 别名 |
B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid;
[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid; Velcade; Radiciol; NSC 681239; DPBA; LDP 341; MG 341; MLN 341; NSC 681239; PS 314; PS 341; Radiciol; Velcade;
|
货号:02-675700
中文名称:硼替佐米
英文名称:Bortezomib-D8 (Major)
CAS号:179324-69-7
重量:1mg
重量:10mg
分子式:C19H25BN4O4
别名:B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid;
[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid; Velcade; Radiciol; NSC 681239; DPBA; LDP 341; MG 341; MLN 341; NSC 681239; PS 314; PS 341; Radiciol; Velcade;
应用介绍:Bortezomib is the first proteasome inhibitor to be approved by the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. Targets the ubiquitin-proteasome pathway.